This study explores a treatment using pembrolizumab to help young patients with certain aggressive brain tumors. Pembrolizumab is a type of immunotherapy that uses the body’s immune system to fight cancer. The study aims to find the safest dose and to understand how well it works in children. It involves treating patients every 21 days for up to 34 cycles, each lasting about 30 minutes. After treatment, patients are checked regularly for up to 3 years. The study is open to children aged 1 to 18, and it requires them to have had prior treatments like radiation or chemotherapy. Patients are followed up to ensure they recover from any side effects. The research team collects samples like blood and spinal fluid to study the treatment's effects. This trial helps researchers learn more about how pembrolizumab works on aggressive brain tumors in children.
- Treatment includes up to 34 cycles, each lasting 21 days.
- Regular follow-ups are conducted for up to 3 years.
- Eligible for children aged 1 to 18 who had prior treatments.